1-20 of 92
Andrew H. Wei
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Clinical Trials & Observations
Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, Hervé Dombret, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, C. L. Beach, Alberto Risueño, Daniel L. Menezes, Gert Ossenkoppele, Hartmut Döhner
Journal: Blood
Blood (2022) 139 (14): 2145–2155.
DOI: https://doi.org/10.1182/blood.2021013404
Published: 2022
Includes: Supplemental data
Journal Articles

Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL

Clinical Trials & Observations
Piers Blombery, Thomas E. Lew, Michael A. Dengler, Ella R. Thompson, Victor S. Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka M. Handunnetti, Dennis A. Carney, David A. Westerman, Constantine S. Tam, Jerry M. Adams, Andrew H. Wei, David C. S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson
Journal: Blood
Blood (2022) 139 (8): 1198–1207.
DOI: https://doi.org/10.1182/blood.2021012775
Published: 2022
Includes: Supplemental data
Journal Articles

Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study

Shaun Fleming, John Reynolds, Ashish Bajel, Nicola Venn, John Kwan, John Moore, David T Yeung, Nalini Pati, Michael F. Leahy, Joanna Nkyekyer, Emma Verner, Leanne Berkahn, Rosemary Sutton, Andrew H. Wei, Matthew Greenwood
Journal: Blood
Blood (2021) 138 (Supplement 1): 1234.
DOI: https://doi.org/10.1182/blood-2021-151826
Published: 2021
Journal Articles

Outcomes for Patients with Late-Stage Mutant- IDH2 (m IDH2 ) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

Courtney D. DiNardo, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Amer M. Zeidan, Iryna Bluemmert, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Stephane de Botton
Journal: Blood
Blood (2021) 138 (Supplement 1): 1243.
DOI: https://doi.org/10.1182/blood-2021-147593
Published: 2021
Journal Articles

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

Courtney D. DiNardo, Hartmut Dohner, Amer M. Zeidan, Andre C. Schuh, Paresh Vyas, Eytan M. Stein, Andrew H. Wei, Stephane de Botton, Clara Chen, Jennifer Lord-Bessen, Patricia Martin-Regueira, Frederik Lersch, Jing Gong, Shien Guo, Ling Shi, Pau Montesinos
Journal: Blood
Blood (2021) 138 (Supplement 1): 1244.
DOI: https://doi.org/10.1182/blood-2021-147601
Published: 2021
Journal Articles

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Ing S Tiong, Sun Loo, Emad Uddin Abro, Devendra Hiwase, Shaun Fleming, Ashish Bajel, Emma Palfreyman, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 1261.
DOI: https://doi.org/10.1182/blood-2021-152583
Published: 2021
Journal Articles

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

Andrew M. Brunner, Elie Traer, Norbert Vey, Sebastian Scholl, Natalia Tovar, Kimmo Porkka, Rupa Narayan, Guillermo Garcia-Manero, Steve Knapper, Martin Wermke, Jeroen J. Janssen, Jordi Esteve, Sun Loo, Mika Kontro, Zachariah Defilipp, Andrew H. Wei, Uma Borate
Journal: Blood
Blood (2021) 138 (Supplement 1): 3677.
DOI: https://doi.org/10.1182/blood-2021-151455
Published: 2021
Journal Articles

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Sylvain Garciaz, Sebastian Müller, Andrew Guirguis, Fiona C. Brown, Yih-Chih Chan, Mathilde Poplineau, Kevin Tran, Kah-Lok Chan, Laura MacPherson, Brian Liddicoat, Enid Y. N. Lam, Tatiana Cañeque, Marian L. Burr, Veronique Litalien, Giovanna Pomilio, Estelle Duprez, David C.S. Huang, Sarah-Jane Dawson, Georg Ramm, Andrew G. Cox, Kristin K. Brown, Andrew H. Wei, Kate McArthur, Raphael Rodriguez, Mark A. Dawson
Journal: Blood
Blood (2021) 138 (Supplement 1): 267.
DOI: https://doi.org/10.1182/blood-2021-145424
Published: 2021
Journal Articles

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Jorge E. Cortes, Jordi Esteve, Ashish Bajel, Karen Yee, Thorsten Braun, Stephane De Botton, Pierre Peterlin, Christian Recher, Xavier Thomas, Justin Watts, Montserrat Arnan Sangerman, Antonio Curti, Carolyn Grove, Brian A. Jonas, Francesco Lanza, Olivier Legrand, Pau Montesinos, Prapti Patel, Thomas Prebet, Eunice S. Wang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Pierre Fenaux, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 698.
DOI: https://doi.org/10.1182/blood-2021-144905
Published: 2021
Journal Articles

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53 -Mutant Acute Myeloid Leukemia

Naval Daver, Paresh Vyas, Mark Chao, Guan Xing, Camille Renard, Giri Ramsingh, David A. Sallman, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 3426.
DOI: https://doi.org/10.1182/blood-2021-145208
Published: 2021
Journal Articles

Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo

Anna Skwarska, Donia M Moujalled, Paul F Panis, Shraddha Patel, Qi Zhang, Shelley Herbrich, Vinitha Kurvilla, Natalia Baran, Giovanna Pomilio, Ensar Halilovic, Prakash Mistry, Vivian Ruvolo, Peter P. Ruvolo, Alix Derréal, Sebastien Banquet, Magdalena Niemira, Adam Kretowski, Naval Daver, Michael Andreeff, Andrew H. Wei, Marina Konopleva
Journal: Blood
Blood (2021) 138 (Supplement 1): 2248.
DOI: https://doi.org/10.1182/blood-2021-151042
Published: 2021
Journal Articles

High Sensitivity Detection of FLT3 -ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

Sun Loo, Richard Dillon, Natasha S Anstee, Ing S Tiong, Adam Ivey, Nicola Potter, Jad Othman, Manohursingh Runglall, Jelena Jovanovic, Amanda Gilkes, Ian Thomas, Sean Johnson, Nigel H. Russell, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 2364.
DOI: https://doi.org/10.1182/blood-2021-149301
Published: 2021
Journal Articles

A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia

Paresh Vyas, Naval Daver, Mark Chao, Guan Xing, Camille Renard, Giri Ramsingh, Andrew H. Wei, David A. Sallman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3424.
DOI: https://doi.org/10.1182/blood-2021-145584
Published: 2021
Journal Articles

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Farhad Ravandi, Hetty E. Carraway, Lilia Taningco, Kimberley Dilley, Eric Laille, Jing Gong, Daniel Lopes de Menezes, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 2314.
DOI: https://doi.org/10.1182/blood-2021-147293
Published: 2021
Journal Articles

A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3 -ITD and CBL -Mutant Acute Myeloid Leukemia (PON-AZA study)

David Kipp, Sun Loo, Andrew Charles Perkins, Steven W Lane, Emily Blyth, Anoop Kumar Enjeti, Ashish Bajel, John Reynolds, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 2350.
DOI: https://doi.org/10.1182/blood-2021-154247
Published: 2021
Journal Articles

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Stephane De Botton, Karen Yee, Christian Recher, Andrew H. Wei, Pau Montesinos, David Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Jordi Esteve, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Olivier Legrand, Pierre Peterlin, Montserrat Arnan Sangerman, William G. Blum, Daniela Cilloni, Devendra Hiwase, Joseph G. Jurcic, Jürgen Krauter, Xavier Thomas, Justin Watts, Jay Yang, Zihao Xin, Alex Sedkov, Sylvie Guichard, Jennifer Sweeney, Christophe Marzac, Jorge E. Cortes, Pierre Fenaux
Journal: Blood
Blood (2021) 138 (Supplement 1): 2351.
DOI: https://doi.org/10.1182/blood-2021-144912
Published: 2021
Journal Articles

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod A. Pullarkat, Brian A. Jonas, Christian Recher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo
Journal: Blood
Blood (2021) 138 (Supplement 1): 224.
DOI: https://doi.org/10.1182/blood-2021-145639
Published: 2021
Journal Articles

Machine Learning of Genomic Factors in 1,961 Patients with Acute Myeloid Leukemia Identifies Patients with Very Good or Very Poor Prognosis Who Do Not Benefit from Allogeneic Hematopoietic Cell Transplant in First Remission

Shaun Fleming, Cheng-Hong Tsai, Hartmut Döhner, Konstanze Döhner, Elli Papaemmanuil, Hwei-Fang Tien, John Reynolds, Andrew H. Wei, Hsin-An Hou
Journal: Blood
Blood (2021) 138 (Supplement 1): 225.
DOI: https://doi.org/10.1182/blood-2021-151972
Published: 2021
Journal Articles

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Jacqueline S. Garcia, Andrew H. Wei, Meagan A. Jacoby, Chun Yew Fong, Uma Borate, Maria R. Baer, Ilona Cunningham, Olatoyosi Odenike, Joseph G. Jurcic, Daniel Nowak, Pierre Peterlin, Uwe Platzbecker, Diana Dunshee, Ying Zhou, David Hoffman, Yan Sun, Relja Popovic, Barrett Ainsworth, Kiran Naqvi, Steve Kye, Leah Hogdal, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 241.
DOI: https://doi.org/10.1182/blood-2021-145613
Published: 2021
Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steve Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia-Manero, Norbert Vey, Martin Wermke, Jeroen Janssen, Rupa Narayan, Sun Loo, Mika Kontro, Oliver Ottmann, Purushotham Naidu, Marc Pelletier, May Han, Andrew Lewandowski, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Uma Borate, Andrew H. Wei, Natalia Tovar
Journal: Blood
Blood (2021) 138 (Supplement 1): 244.
DOI: https://doi.org/10.1182/blood-2021-146039
Published: 2021